High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply

Affiliations

¹ Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK. Electronic address: leon.peto@ndph.ox.ac.uk.
² Patan Academy of Health Sciences, Lalitpur, Nepal.
³ Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LF, UK.

Comment

Leon Peto et al. Lancet. 2024.

. 2024 Apr 6;403(10434):1339-1340.

doi: 10.1016/S0140-6736(23)02879-9.

¹ Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK. Electronic address: leon.peto@ndph.ox.ac.uk.
² Patan Academy of Health Sciences, Lalitpur, Nepal.
³ Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LF, UK.

No abstract available

Comment on

High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
Hashim Z, Nath A, Tripathy NK. Hashim Z, et al. Lancet. 2024 Apr 6;403(10434):1337-1338. doi: 10.1016/S0140-6736(23)02882-9. Lancet. 2024. PMID: 38582559 No abstract available.
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
McEvoy N, Lowry J, O'Dowd A, Curley GF, Fitzpatrick F. McEvoy N, et al. Lancet. 2024 Apr 6;403(10434):1337. doi: 10.1016/S0140-6736(23)02880-5. Lancet. 2024. PMID: 38582560 No abstract available.
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
Hsu NC, Tokuda Y. Hsu NC, et al. Lancet. 2024 Apr 6;403(10434):1338. doi: 10.1016/S0140-6736(23)02883-0. Lancet. 2024. PMID: 38582561 No abstract available.
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
Narasaraju T, Ravi Y, Jonsson CB, Chow VTK. Narasaraju T, et al. Lancet. 2024 Apr 6;403(10434):1338-1339. doi: 10.1016/S0140-6736(23)02884-2. Lancet. 2024. PMID: 38582562 No abstract available.
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
Bhusal S, Adhikari S. Bhusal S, et al. Lancet. 2024 Apr 6;403(10434):1339. doi: 10.1016/S0140-6736(23)02881-7. Lancet. 2024. PMID: 38582563 No abstract available.